Cochrane · systematic review · CD008337
Optimum duration of regimens for Helicobacter pylori eradication
Yuan, Y, Ford, AC, Khan, KJ, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
17
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 11.8%Low 6 · 35.3%Moderate 9 · 52.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PPI triple therapy for 14 days versus 7 days for Helicobacter pylori eradication
Population: patients with Helicobacter pylori infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
H. pylori persistence, regardless of regimen and dose PPI triple therapy for 14 days vs 7 days | RR 0.66 [0.6, 0.74] | 45 studies · 7722 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PCA subgroup PPI triple therapy for 14 days vs 7 days | RR 0.65 [0.57, 0.75] | 34 studies · 5801 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PCN subgroup PPI triple therapy for 14 days vs 7 days | RR 0.87 [0.71, 1.07] | 4 studies · 688 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
H. pylori persistence, PAN subgroup PPI triple therapy for 14 days vs 7 days | RR 0.67 [0.52, 0.86] | 10 studies · 1066 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PAQ subgroup PPI triple therapy for 14 days vs 7 days | RR 0.37 [0.16, 0.83] | 2 studies · 167 participants | Low Downgraded: risk of bias, imprecision |
Patients with adverse events, regardless of regimen and dose PPI triple therapy for 14 days vs 7 days | RR 1.2 [1.06, 1.37] | 25 studies · 3971 participants | Moderate Downgraded: risk of bias, inconsistency |
PPI triple therapy for 10 days versus 7 days for Helicobacter pylori eradication
Population: patients with Helicobacter pylori infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
H. pylori persistence, regardless of regimen and dose PPI triple therapy for 10 days vs 7 days | RR 0.8 [0.72, 0.89] | 24 studies · 4628 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PCA subgroup PPI triple therapy for 10 days vs 7 days | RR 0.8 [0.7, 0.91] | 17 studies · 3271 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PCN subgroup PPI triple therapy for 10 days vs 7 days | RR 0.99 [0.55, 1.79] | 2 studies · 148 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
H. pylori persistence, PAN subgroup PPI triple therapy for 10 days vs 7 days | RR 0.85 [0.65, 1.12] | 4 studies · 573 participants | Low Downgraded: risk of bias, inconsistency, publication bias |
H. pylori persistence, PAQ subgroup PPI triple therapy for 10 days vs 7 days | RR 0.58 [0.36, 0.95] | 2 studies · 346 participants | Low Downgraded: risk of bias, imprecision, publication bias |
H. pylori persistence, PANi subgroup PPI triple therapy for 10 days vs 7 days | RR 0.79 [0.52, 1.2] | 1 study · 290 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Patients with adverse events, regardless of regimen and dose PPI triple therapy for 10 days vs 7 days | RR 1.06 [0.87, 1.3] | 11 studies · 2089 participants | Moderate Downgraded: risk of bias, inconsistency |
PPI triple therapy for 14 days versus 10 days for Helicobacter pylori eradication
Population: patients with Helicobacter pylori infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
H.pylori persistence, regardless of regimen and dose PPI triple therapy for 14 days vs 10 days | RR 0.72 [0.58, 0.9] | 12 studies · 2111 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H.pylori persistence, PCA subgroup PPI triple therapy for 14 days vs 10 days | RR 0.69 [0.52, 0.91] | 10 studies · 1596 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
H.pylori persistence, PAN subgroup PPI triple therapy for 14 days vs 10 days | RR 0.79 [0.54, 1.15] | 4 studies · 515 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Patients with adverse events, regardless of regimen and dose PPI triple therapy for 14 days vs 10 days | RR 1.01 [0.79, 1.29] | 5 studies · 789 participants | Low Downgraded: risk of bias, inconsistency, publication bias |